This blog post has been funded by an educational grant from Bristol Myers Squibb.
Immunotherapy has become an important treatment option for many people living with kidney cancer. While these medicines have traditionally been given through an IV infusion, some immunotherapies are now also available as a subcutaneous injection. Understanding how these options compare can help patients have more informed conversations with their care team about what may work best for them.
Hear from a kidney cancer patient, Michelle Picolo, about her experience switching from immunotherapy infusions to subcutaneous immunotherapy.
